Bio-Discovery Up as Invitrogen Posts 14.8 Percent Spike in Q3 Revs
Invitrogen this week reported receipts of $361.7 million in its third quarter, up 14.8 percent from $315 million a year ago. That includes a 13.2 percent increase in its Bio-Discovery segment, which houses its proteomics tools and consumables, to $249.4 million from $220.4 million a year ago.
Cell Systems, Invitrogen’s other segment, saw revenues grow to $112.3 million, up 18.7 percent from $94.6 million a year ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Sponsored by
Twist Bioscience

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.